FOR ANIMAL USE ONLY

BRAVECTO® SPOT-ON
Reg. No. G4292 (Act 36/1947)
Namibia Reg. No. V19/18.3.10/1441 NS0

INDICATIONS
For the treatment and prevention of tick, flea and mite infestations in dogs and cats.
Bravecto® Spot-On can be used as part of a treatment strategy for Flea Allergy Dermatitis (FAD). For the treatment of mange caused by *Demodex* spp. and *Sarcoptes scabiei* mites in dogs. For the treatment of *Otodectes* spp. mite infestations in dogs and cats.
In cats, **Bravecto® Spot-On** provides immediate and persistent flea and tick killing activity for 3 months.
In dogs, **Bravecto® Spot-On** provides immediate and persistent tick killing activity for 4 months and flea killing activity for 6 months. **Bravecto® Spot-On** is well tolerated in MDR1 dogs.

A single treatment prevents *Dipylidium caninum* transmission from infected fleas to susceptible dogs for 12 weeks.

COMPOSITION
Each 1 mℓ of **Bravecto® Spot-On** contains 280 mg fluralaner.
Each pipette delivers:

Miniature dogs:	112,5 mg fluralaner	Small cats:	112,5 mg fluralaner
Small dogs:	250 mg fluralaner	Medium cats:	250 mg fluralaner
Medium dogs:	500 mg fluralaner	Large cats:	500 mg fluralaner
Large dogs:	1 000 mg fluralaner		
Extra-large dogs:	1 400 mg fluralaner		

CLINICAL PHARMACOLOGY
Peak fluralaner concentrations are achieved between 7 and 42 days following topical administration and the elimination half-life ranges between 14 and 29 days. The bioavailability of fluralaner following oral and topical administration is approximately 25 %.

PHARMACODYNAMIC PROPERTIES
Fluralaner is an acaricide and insecticide. It is efficacious against ticks, fleas and mites.
Fluralaner is for systemic use and belongs to the class of isoxazoline-substituted benzamide derivatives.
Fluralaner is an inhibitor of parts of the arthropod nervous system. The mode of action of fluralaner is the antagonism of the ligand-gated chloride channels (gamma-aminobutyric acid (GABA)-receptor and glutamate-receptor).

CAUTION

STORAGE
Store at or below 30 °C in a cool, dry place.

WARNINGS
- Handle with caution.
- For cats, safety has not been established during pregnancy and lactation. Use only according to the benefit/risk assessment by the responsible veterinarian.
- For dogs infected with tapeworm, we recommend a suitable tapeworm treatment be used.
- Do not use in the case of hypersensitivity to the active substance or to any of the excipients.
- Parasites need to start feeding on the host to become exposed to fluralaner; therefore, the risk of the transmission of parasite-borne diseases cannot be excluded but is reduced by the speed of efficacy.
- Care should be taken to avoid contact with the eyes of the animal.

- Do not use directly on skin lesions.
- Dogs can be washed/shampooed 3 days after treatment.
- Safety in puppies less than 8 weeks old and/or dogs weighing less than 2 kg has not been established.
- Safety in kittens less than 9 weeks old and/or cats weighing less than 1,2 kg has not been established.
- The product should not be administered at intervals shorter than 8 weeks as the safety for shorter intervals has not been tested.
- Keep the product in the original packaging until use.
- **Do not have contact with the animal or allow children to have contact with the animal until the application site is dry.**
- The product is highly flammable. Keep away from heat, sparks, open flames or other sources of ignition.
- KEEP OUT OF REACH OF CHILDREN, UNINFORMED PERSONS AND ANIMALS.
- Although this remedy has been extensively tested under a large variety of conditions, failure thereof may ensue as a result of a wide range of reasons. If this is suspected, seek veterinary advice and notify the registration holder.

PRECAUTIONS
- For topical use only. Avoid oral ingestion.
- Do not eat, drink or smoke while handling the product.
- Wash hands thoroughly with soap and water immediately after the product has been used. If skin contact does occur, wash the affected area immediately with water. In some cases, water is not sufficient to remove the product spilled on the fingers. If a sticky residue persists on the skin after washing with water, then this can be removed using household items containing organic solvents [e.g., rubbing alcohol (ethanol, isopropyl alcohol) or nail polish remover (acetone)] applied gently with a swab.
- Do not store with food, drinks, medication or household products.
- Medicines should not be disposed of via wastewater or household waste but in accordance with the National Environmental Management: Waste Act, 2008 (Act No. 59 of 2008). These measures should help to protect the environment.

INTERACTIONS
Fluralaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the coumarin derivative warfarin. Incubation of fluralaner in the presence of carprofen or warfarin in dog plasma at maximum expected plasma concentrations did not reduce the protein binding of fluralaner, carprofen or warfarin.
During laboratory and clinical field testing, no interactions between **Bravecto® Spot-On** and routinely used veterinary medicinal products were observed.

ADVERSE REACTIONS
Commonly observed adverse reactions in clinical trials were mild and transient skin reactions at the application site (1,2 % of treated dogs and 2,2 % of treated cats). Cat's skin reactions were such as erythema and pruritus (most likely due to a transient discomfort) or alopecia (secondary effect due to scratching or licking).
As a result of transient discomfort shortly after administration, the following signs were observed: apathy/tremors/anorexia (0,9 % of treated cats) or vomiting/hypersalivation (0,4 % of treated cats).
Emesis, lethargy and inappetence have been reported very rarely in spontaneous reports after the use of this product.
If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinarian.

DIRECTIONS FOR USE - USE ONLY AS DIRECTED

Bravecto® Spot-On should be administered in accordance with the following table (corresponding to a dose of between 25 and 56 mg fluralaner/kg body weight in dogs and between 40 and 94 mg fluralaner/kg body weight in cats within one weight band):

Weight of dog/cat (kg)	Pipette size to be used	Volume (mℓ)	Fluralaner (mg)
2 - 4,5	Miniature dogs	0,4	112,5
> 4,5 - 10	Small dogs	0,89	250
> 10 - 20	Medium dogs	1,79	500
> 20 - 40	Large dogs	3,57	1 000
> 40 - 56	Extra-large dogs	5,0	1 400
> 56	The appropriate combination of pipettes should be used.		
1,2 - 2,8	Small cats	0,4	112,5
> 2,8 - 6,25	Medium cats	0,89	250
> 6,25 - 12,5	Large cats	1,79	500

For optimal control of tick infestation, **Bravecto® Spot-On** should be administered every 3 months for cats and every 4 months for dogs.
For optimal control of flea infestation, **Bravecto® Spot-On** should be administered every 3 months for cats and every 6 months for dogs.
Within each weight range a whole pipette must be used.
For dogs weighing more than 56 kg, use a combination of 2 pipettes that most closely matches the body weight.
For cats weighing more than 12,5 kg, use a combination of 2 pipettes that most closely matches the body weight.

Method of administration
Step 1
Open the sachet and remove the pipette immediately before use. The pipette should be held by the upper part of the tail base (crimped end) or by the upper rigid portion below the cap in an upright position (tip up) before opening it. The cap should be rotated clockwise or counterclockwise in one full turn. **The cap will stay on the pipette; it should not be removed**. The pipette is open and ready for application when the breaking of the seal is felt.



Step 2
The dog/cat should be standing or lying with its back horizontally during application. Part the fur at the administration site. Place the pipette tip vertically against the skin between the shoulder blades of the dog or on the base of the skull of the cat.

Step 3
Dogs:
Squeeze the pipette gently and apply the entire contents directly to the dog's skin in one go (when volume is small) or several spots along the dog's dorsal line from the shoulder to the base of the tail. Avoid applying an excessive amount of solution at any one spot that could cause some of the solution to run or drip off the dog.





Cats

Squeeze the pipette gently and apply the entire contents directly to the cat's skin. The product should be applied in one spot (cats up to 6,25 kg body weight) or two spots (cats weighing more than 6,25 kg body weight). If two spots are needed, the first spot should be applied at the base of the skull and the second spot between the shoulder blades.

It is important to deliver the solution onto an area that cannot be easily licked by the cat. As cats are fastidious groomers, they may inadvertently ingest product if easily reached. Ingestion may cause adverse reactions and will remove product from the coat. If multiple cats are treated and may mutually groom, it is recommended that cats are separated while product dries.

OVERDOSE

Dogs

Safety was demonstrated in puppies aged between 8 and 9 weeks and weighing between 2,0 and 3,7 kg treated with overdoses of up to 5 times the maximum recommended dose on 3 occasions at shorter intervals than recommended (8-week intervals).

Safety was demonstrated in breeding, pregnant and lactating dogs treated with overdoses of up to 3 times the maximum recommended dose.

Bravecto® Spot-On was well tolerated in Collie dogs with a deficient multidrug-resistance-protein 1 (MDR1 -/-) following single oral administration at 3 times the recommended dose.

Cats

Safety was demonstrated in kittens aged between 11 and 13 weeks and weighing between 1,2 and 1,5 kg treated with overdoses of up to 5 times the maximum recommended dose on 3 occasions at shorter intervals than recommended (8-week intervals).

Oral uptake of **Bravecto® Spot-On** at the maximum recommended dose was, both locally and systemically, well tolerated in cats, apart from some self-limiting salivation and coughing immediately after administration.

In cats, safety has not been established during pregnancy and lactation.

EFFICACY

Bravecto® Spot-On was shown to be effective against ticks, fleas and mites.

It is a systemic insecticide and acaricide.

Cats: the product provides immediate and persistent flea and tick killing activity for 3 months.

Dogs: the product provides immediate and persistent tick killing activity for 4 months and flea killing activity for 6 months.

Ticks and fleas must attach to the host and commence feeding in order to be exposed to the active substance. The onset of effect is within 8 hours.

Bravecto® Spot-On is efficacious for the treatment of the following:

Ticks
Dogs: *Ixodes ricinus, Rhipicephalus sanguineus, Haemaphysalis elliptica* and *Dermacentor reticulatus.*
Cats: *Ixodes ricinus* and *Haemaphysalis elliptica.*

Directly after treatment, at least 90 % of ticks on the animals are killed within 8 hours. During the whole treatment interval, at least 90 % of ticks on the animals are killed within 12 hours.

Fleas
Dogs: *Ctenocephalides felis* and *Ctenocephalides canis.*
Cats: *Ctenocephalides felis.*

Directly after treatment, at least 95 % of fleas are killed within 8 hours.
During the whole treatment interval, at least 95 % of fleas on dogs are killed within 12 hours.

Control of flea infestations and Flea Allergy Dermatitis (FAD)
The flea life cycle is broken due to the rapid onset action and long-lasting efficacy against adult fleas on the animal and the absence of viable egg production. **Bravecto® Spot-On** effectively controls environmental flea populations in areas to which the animals have access.

Effect on immature stages
The product kills adult as well as juvenile ticks (larvae, nymphs). Newly emerged fleas on animals are killed before viable eggs are produced. An *in vitro* study also demonstrated that very low concentrations of fluralaner stop the production of viable eggs by fleas.

Mites
Dogs: Mange caused by *Demodex* spp. and *Sarcoptic* mange mites. For the treatment of *Otodectes* spp. mite infestations.
Cats: *Otodectes* spp.

PRESENTATION
Unit dose pipette made of laminated aluminium/polypropylene foil containing a colourless to yellowish solution, practically free from visible particles closed with cap and packed in a sachet. Each carton box contains 1 or 2 pipettes.

REGISTRATION HOLDER
Intervet South Africa (Pty) Ltd.
20 Spartan Road, Spartan
1619, RSA
Tel: +27 (0) 11 923 9300
Fax: +27 (0) 11 392 3158
www.msd-animal-health.co.za

MANUFACTURER
Patheon Manufacturing Services LLC
5900 Martin Luther King Jr. Highway
Greenville, North Carolina (NC) 27834
United States of America

DATE OF PUBLICATION OF THIS PACKAGE INSERT
10 June 2021

MSD Animal Health

SLEGS VIR DIEREGEBRUIK

BRAVECTO® SPOT-ON SOLUTION
Reg. Nr. G4292 (Wet 36/1947)
Namibië Reg. Nr. V19/18.3.10/1441 NS0

INDIKASIES
Vir die behandeling en voorkoming van vlooi-, bosluis- en mytinfestasies in honde en katte. **Bravecto® Spot-On** kan gebruik word as deel van 'n behandelingstrategie vir Vlooi Allergiese Dermatitis (VAD). Vir die behandeling van skurfte wat veroorsaak word deur *Demodex* spp. en *Sarcoptes scabiei* myte by honde. Vir die behandeling van *Otodectes* spp. mytinfestasies in honde en katte.
In katte het **Bravecto® Spot-On** 'n onmiddellike en aanhoudende vlooi- en bosluisdodende aktiwiteit vir 3 maande.
In honde het **Bravecto® Spot-On** 'n onmiddellike en aanhoudende bosluisdodende aktiwiteit vir 4 maande asook 'n vlooidodende aktiwiteit vir 6 maande. **Bravecto® Spot-On** word goed verdra in MDR1 honde.

'n Enkele behandeling verhoed dat *Dipylidium caninum*-oordrag vanaf besmette vlooie na vatbare honde vir 12 weke voorkom.

SAMESTELLING
Elke 1 mℓ **Bravecto® Spot-On** bevat 280 mg fluralaner.
Elke pipet verskaf:

Miniatuur honde:	112,5 mg fluralaner	Klein katte:	112,5 mg fluralaner
Klein honde:	250 mg fluralaner	Medium katte:	250 mg fluralaner
Medium honde:	500 mg fluralaner	Groot katte:	500 mg fluralaner
Groot honde:	1 000 mg fluralaner		
Ekstra Groot honde:	1 400 mg fluralaner		

KLINIESE FARMAKOLOGIE
Piek fluralanerkonsentrasies word tussen 7 en 42 dae na topikale toediening bereik en die eliminasie halfleeftyd wissel tussen 14 en 29 dae. Die biobeskikbaarheid van fluralaner na orale- en topikale toediening is ongeveer 25 %.

FARMAKODINAMIESE EIENSKAPPE
Fluralaner is 'n myt- en insekdoder. Dit is effektief teen bosluise, vlooie en myte.
Fluralaner is vir sistemiese gebruik en behoort aan die klas isoksasolien-vervangde bensamied-derivate.
Fluralaner is 'n inhibeerder van 'n gedeelte van die geleedpotige se senuweestelsel deur antagonisties op die ligandbeheerde chloriedkanale (gamma-aminobutuursuur (GABA)-reseptor en glutamaat-reseptor) te werk.

VERSIGTIG

BERGING
Berg teen of benede 30 °C in 'n koel, droë plek.

WAARSKUWINGS
- Hanteer versigtig.
- Vir katte is die veiligheid gedurende dragtigheid en laktasie nog nie vasgestel nie. Gebruik slegs volgens die voordeel/risiko-assessering deur die verantwoordelike veearts.
- Moenie gebruik in die geval van hipersensitiwiteit teenoor die aktiewe bestanddele of enige van die onaktiewe bestanddele nie.

- Parasiete moet begin voed op die gasheer om blootgestel te word aan fluralaner; daarom kan die risiko van parasietoorgedraagde siektes nie uitgesluit word nie, maar dit kan verminder word deur die snelheid van effektiwiteit.
- Sorg moet gedra word om kontak met die dier se oë te vermy.
- Moenie direk op velletsels gebruik nie.
- Honde kan gewas/gesjampoe word 3 dae na behandeling.
- Veiligheid in hondjies jonger as 8 weke en/of honde wat minder as 2 kg weeg is nog nie bepaal nie.
- Veiligheid in katjies jonger as 9 weke en/of katte wat minder as 1,2 kg weeg is nog nie bepaal nie.
- Die produk moenie toegedien word teen intervalle korter as 8 weke nie, aangesien die veiligheid van korter intervalle nie getoets is nie.
- Hou die produk in die oorspronklike verpakking tot voor gebruik.
- **Moenie diere aanraak of kinders toelaat om die diere aan te raak totdat die toedieningsarea droog is nie.**
- Die produk is hoogs vlambaar. Hou weg van hitte, vonke, oop vlamme en ander vorms van ontbranding.
- HOU BUITE BEREIK VAN KINDERS, ONINGELIGTE PERSONE EN DIERE.
- Alhoewel hierdie middel breedvoerig onder 'n wye verskeidenheid toestande getoets is, mag dit faal as gevolg van verskeie redes. Indien dit vermoed word, raadpleeg 'n veearts en verwittig die registrasiehouer.

VOORSORGMAATREëLS

- Vir topikale gebruik alleenlik. Vermy orale inname.
- Moenie eet, drink of rook terwyl die produk hanteer word nie.
- Was hande deeglik met seep en water direk nadat die produk gebruik is. Indien velkontak voorkom, was die betrokke area dadelik met water. In sommige gevalle is water nie voldoende om die produk wat op die vingers gespat het, te verwyder nie. Indien ‘n taai residu agterbly op die vel nadat dit met water gewas is, kan dit verwyder word deur gebruik te maak van huishoudelike items wat organiese oplosmiddels bevat, [bv. chirurgiese alkohol (etanol, isopropielalkohol) of naellakverwyderaar (asetoon)].
- Moenie saam met kos, drank, medikasie of huishoudelike produkte stoor nie.
- Medisyne moenie weggedoen word via afvalwater of huishoudelike afval nie maar volgens die Nasionale Omgewingsbestuur: Afval Bestuur Wet, 2008 (Wet Nr. 59 van 2008). Hierdie maatreëls behoort te help om die omgewing te beskerm.

INTERAKSIES

Fluralaner is hoogs plasmaproteïengebonde en kan kompeteer met ander hoogs gebonde middels soos nie-steroïede anti-inflammatoriese middels (NSAIMs) en die kumarienderivaat van warfarin. Inkubasie van fluralaner in die teenwoordigheid van karprofen of warfarin in die hondplasma teen maksimum verwagte plasmakonsentrasies, het nie die proteïenbinding van fluralaner, karprofen of warfarin verminder nie.
Gedurende laboratorium- en kliniese veldtoetse is geen interaksie tussen **Bravecto® Spot-On** en dieremedisyne wat gereeld gebruik word, waargeneem nie.

NEWE-EFFEKTE

Newe-effekte wat algemeen waargeneem is in kliniese proewe, was lig, en verbygaande velreaksies by die toedieningspunt (1,2 % van die behandelde honde en 2,2 % van behandelde katte). Katte se velreaksies het eriteem en pruritus (waarskynlik as gevolg van verbygaande ongerief) of alopesie (sekondêre effek weens krap of lek) ingesluit.
As gevolg van verbygaande ongerief, is die volgende tekens na toediening waargeneem: apatie/bewerigheid/anoreksie (0,9 % van die behandelde katte) of braking/hipersalivering (0,4 % van die behandelde katte).

Na spontane verslae na die gebruik van hierdie produk is daar selde melding gemaak van uitbarsting, lusteloosheid en swakheid.

As u enige ernstige gevolge of ander effekte wat nie in hierdie voubiljet genoem word nie waarneem, stel asseblief u veearts in kennis.

GEBRUIKSAANWYSINGS - GEBRUIK SLEGS SOOS AANGEDUI

Bravecto® Spot-On moet in ooreenstemming met die volgende tabel toegedien word (wat ooreenstem met 'n dosis van tussen 25 en 56 mg fluralaner/kg liggaamsgewig in honde en tussen 40 en 94 mg fluralaner/kg liggaamsgewig in katte binne een gewigsband):

Gewig van hond/kat (kg)	Pipetgrootte vir gebruik	Volume (mℓ)	Fluralaner (mg)
2 - 4,5	Miniatuur honde	0,4	112,5
> 4,5 - 10	Klein honde	0,89	250
> 10 - 20	Medium honde	1,79	500
> 20 - 40	Groot honde	3,57	1 000
> 40 - 56	Ekstra Groot honde	5,0	1 400
> 56	Die gepaste kombinasie van pipette moet gebruik word		
1,2 - 2,8	Klein katte	0,4	112,5
> 2,8 - 6,25	Medium katte	0,89	250
> 6,25 - 12,5	Groot katte	1,79	500

Vir optimale beheer van bosluisinfestasie, moet **Bravecto® Spot-On** elke 3 maande vir katte en elke 4 maande vir honde, toegedien word.

Vir optimale beheer van vlooi-infestasie, moet **Bravecto® Spot-On** elke 3 maande vir katte en elke 6 maande vir honde toegedien word.

Binne elke gewigsreeks moet 'n hele pipet gebruik word.

Honde wat meer as 56 kg weeg, moet 'n kombinasie van 2 pipette gebruik wat die naaste aan die liggaamsgewig is.

Katte wat meer as 12,5 kg weeg, moet 'n kombinasie van 2 pipette gebruik wat die naaste aan die liggaamsgewig is.

Toedieningsmetode

Stap 1

Onmiddellik voor gebruik, maak die sakkie oop en verwyder die pipet. Die pipet moet vasgehou word op die boonste gedeelte van die stertbasis (geriffelde punt) of deur die boonste stewige gedeelte onder die doppie in 'n regop posisie te hou (doppie boontoe) voordat dit oopgemaak word. Die doppie moet kloksgewys of antikloksgewys gedraai word vir een volle draai. **Die doppie sal op die pipet bly; dit is nie moontlik om dit te verwyder nie**. Die pipet is oop en gereed vir toediening wanneer die verbreking van die seël gevoel word.





Stap 2

Die hond/kat moet staan of met sy rug horisontaal lê tydens toediening. Skei die hare by die toedieningsplek. Plaas die pipetpunt vertikaal teen die vel tussen die skouerblaaie van die hond of op die basis van die skedel van die kat.

Stap 3

Honde

Druk die pipet liggies en dien die hele inhoud direk op die hond se vel op een plek (wanneer die volume klein is) of op 'n paar plekke langs die hond se dorsale lyn van die skouer tot by die basis van die stert. Vermy om 'n oormatige hoeveelheid oplossing op een plek toe te dien, wat kan veroorsaak dat die oplossing van die hond afloop of afdrup.



Katte

Druk die pipet liggies en dien die volle inhoud direk op die kat se vel toe. Die produk moet toegedien word op een (katte wat tot en met 6,25 kg liggaamsgewig weeg) of twee plekke (katte wat meer as 6,25 kg liggaamsgewig weeg). As twee plekke nodig is, moet die eerste plek op die basis van die skedel en die tweede plek tussen die skouerblaaie wees.

Dit is belangrik om die oplossing toe te dien op 'n area wat nie maklik deur die kat gelek kan word nie. Aangesien katte puntenerige versorgers is, kan hulle per ongeluk die produk inneem as dit te maklik bereik kan word. Inname mag ongewenste reaksies veroorsaak en sal die produk van die pels verwyder. Indien meer katte behandel word wat mekaar onderling versorg, word aanbeveel dat katte geskei word terwyl die produk droog word.

OORDOSERING

Honde

Veiligheid is gedemonstreer in hondjies tussen die ouderdom van 8 en 9 weke en met 'n gewig van tussen 2,0 en 3,7 kg wat behandel is met tot 5 keer die maksimum aanbevole dosis by drie geleenthede en met korter tussenposes as die aanbevole, 8-week intervalle. Veiligheid is gedemonstreer in teel-, dragtige- en lakterende honde behandel met oordosisse van tot 3 keer die maksimum aanbevole dosis.

Bravecto® Spot-On is goed verdra in Kolliehonde met 'n gebrekkige multi-weerstand-proteïen-1 (MDR1 -/-) na 'n enkele orale toediening teen 3 keer die aanbevole dosis.

Katte

Veiligheid is gedemonstreer in katjies tussen die ouderdom van 11 en 13 weke en met 'n gewig van tussen 1,2 en 1,5 kg behandel met oordosisse van tot 5 keer die maksimum aanbevole dosis by 3 geleenthede, met korter tussenposes as die aanbevole, 8-week intervalle.

Orale opname van **Bravecto® Spot-On** teen die maksimum aanbevole dosis word beide lokaal en sistemies, goed verdra in katte, afgesien van sommige selfbeperkende speekselafskeiding en hoes gevalle onmiddellik na toediening.

In katte is die veiligheid gedurende dragtigheid en laktasie nog nie vasgestel nie.

DOELTREFFENDHEID

Daar is bewys dat **Bravecto® Spot-On** effektief teen bosluise, vlooie en myte gebruik kan word. Dit is 'n sistemiese insek- en mytdoder.

In katte: Die produk lewer onmiddellike en aanhoudende vlooi- en bosluisdodende aktiwiteit vir 3 maande.

In honde: Die produk lewer onmiddellike en aanhoudende bosluisdodende aktiwiteit vir 4 maande, en vlooidodende aktiwiteit vir 6 maande.

Bosluise en vlooie moet aan die gasheer vasheg en begin voed om in aanraking met die aktiewe bestanddeel te kom. Die aanvangseffek is binne 8 ure.

Bravecto® Spot-On is effektief vir die behandeling van die volgende:
Bosluise
Honde: *Ixodes ricinus, Rhipicephalus sanguineus, Haemaphysalis elliptica* en *Dermacentor reticulatus.*
Katte: *Ixodes ricinus* en *Haemaphysalis elliptica.*

Direk na behandeling, word 90 % van die bosluise binne 8 uur gedood. Tydens die totale behandelingsinterval, word 90 % van die bosluise op die diere binne 12 uur gedood.

Vlooie
Honde: *Ctenocephalides felis* en *Ctenocephalides canis.*
Katte: *Ctenocephalides felis.*

Direk na behandeling gaan ten minste 95 % vlooie binne 8 ure dood. Gedurende die hele behandelingsinterval gaan minstens 95 % van die vlooie op honde binne 12 ure dood.

Beheer van vlooi-infestasies en Vlooi Allergiese Dermatitis (VAD)
Die vlooi se lewenssiklus word verbreek deur middel van die vinnige werking en die langwerkende effektiwiteit teen die volwasse vlooie op die dier, sowel as die afwesigheid van lewensvatbare eierproduksie. **Bravecto® Spot-On** beheer vlooipopulasies in die omgewing effektief in areas waartoe die diere toegang het.

Effek op onvolwasse stadia
Die produk maak volwasse sowel as onvolwasse bosluise (larwes en nimfe) dood. Nuut uitgebroeide vlooie op honde gaan dood voordat lewensvatbare eiers geproduseer kan word. 'n *In vitro* studie het ook getoon dat baie lae konsentrasies fluralaner, die produksie van lewensvatbare eiers deur vlooie kan verhoed.

Myte
Honde: Skurfte veroorsaak deur *Demodex* spp. en *Sarcoptes* skurftemyte. Vir die behandeling van *Otodectes* spp. mytbesmettings.
Katte: *Otodectes* spp.

AANBIEDING
Eenheidsdosispipet gemaak van gelamineerde aluminium/polipropileenfoelie met 'n kleurlose tot gelerige oplossing, feitlik vry van sigbare deeltjies, gesluit met 'n doppie en verpak in 'n sakkie. Elke kartonboks bevat 1 pipet.

REGISTRASIEHOUER
Intervet South Africa (Pty) Ltd.
Spartanweg 20, Spartan
1619, RSA
Tel: +27 (0) 11 923 9300
Faks: +27 (0) 11 392 3158
www.msd-animal-health.co.za

VERVAARDIGER
Patheon Manufacturing Services LLC
5900 Martin Luther King Jr. Highway
Greenville, North Carolina (NC) 27834
United States of America

DATUM VAN PUBLIKASIE VAN HIERDIE VOUBILJET
10 Junie 2021

MSD Animal Health